Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

MedX Health Corp. (V:MDX)

Business Focus: Advanced Medical Equipment & Technology (NEC)

Feb 28, 2024 09:08 am ET
MedX Health and Health Partners announce the successful results of its pilot project in the United Kingdom and move towards a partnership agreement
MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce they have successfully completed the pilot project with Health Partners. MedX and Health Partners are working together to begin the roll-out of this service to targeted clients engaged in a preventative approach to health care management.
Jan 25, 2024 12:00 pm ET
MedX Health Corp. announces Dr. Paul Cohen as Medical Spokesperson
MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) is pleased to announce that it has appointed Dr. Paul Cohen, a board-certified dermatologist and Fellow of the Royal College of Physicians and Surgeons of Canada, as Medical Spokesperson. Dr. Cohen is also a diplomat of the American Board of Dermatology and is a member of numerous associations, including the Canadian Dermatological Association and the Toronto Dermatological Society. He was awarded the Ben Fisher Galderma fellowship in clinical dermatology, where he completed additional training in cosmetic, surgical and pediatric d
Dec 12, 2023 04:57 pm ET
MedX Announces Intention to Seek Acceptance for Amendment to Series I Convertible Loan Notes
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is making an Application to the TSX-V for Acceptance of the proposed amendment to the terms of the currently outstanding Convertible Loan Notes (“Series I Notes”). Following the conversion of five Series I Loan Notes during 2021, there are currently 75 Series I Loan Notes outstanding, with a face value of $3,750,000. The Series I Loan Notes, originally issued in the First Quarter of 2021, pay Interest quarterly at 6% per year, mature on December 31, 2023 (“Original Matu
Nov 21, 2023 09:16 am ET
MedX Health Corp. Announces Conversion of $2.965 Million of Secured Convertible Debentures
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that, effective November 17, 2023, $2,965,000 of Secured Convertible Debentures were fully redeemed pursuant to exercise of the Conversion Rights by the Holders, resulting issuance of 59,300,000 common shares and 59,300,000 share purchase warrants exercisable at $0.20 until December 31, 2027.
Nov 14, 2023 09:13 am ET
MedX Health Corp. Announces Closing of Non-Brokered Private Placement and Amendment of Terms of Warrants Issued in April, May and July, 2020
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced today that, it has submitted for Final Acceptance from the TSXV and has closed the non-brokered Private Placement which was previously announced on August 30, 2023. The placement, to accredited investors, raised $1,020,000 by issuance of 14,571,428 units at $0.07 per unit (“Unit”). Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.12, exercisable for a period commencing on the date of issue and expir
Nov 01, 2023 05:48 pm ET
MedX Announces the Appointment of Jeffrey Morris as VP of Sales and Marketing
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce the appointment of veteran healthcare industry leader Jeffrey Morris as Vice President of Sales and Marketing.
Oct 12, 2023 05:10 pm ET
MedX Health Corp. Announces Proposed Extension of Non-Brokered Private Placement Offering
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced today that, subject to acceptance by the TSX-V, the ultimate Closing Date for the non-brokered Private Placement of up to $1.5 million, which was previously announced on August 30, 2023, will be extended by up to 30 days. The Company has already received Conditional Acceptance for the placement from the TSX-V, but closing for the full amount of the proposed Placement has been delayed. The proposed placement, to accredited investors, is for the placement of up to 21,428,571 units at $0.07per unit (“Unit”). Each Uni
Sep 21, 2023 11:27 pm ET
TSX Venture Exchange Stock Maintenance Bulletins
VANCOUVER, BC, Sept. 21, 2023 /CNW/ -
Aug 30, 2023 08:14 am ET
MedX Announces proposed Non-Brokered Private Placement to raise up to $1,500,000 and intention to seek Acceptance for Amendment to Warrants
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is proposing to raise up to $1,500,000 by way of a Non-Brokered Private Placement of up to 21,428,571 Units at $0.07 per Unit (“Unit”). Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.12, exercisable for a period commencing on the date of issue and expiring on December 31, 2026. Closing of the Placement, which may take place in tranches, will be subject to re
Jun 19, 2023 08:30 am ET
MedX Announces Intention to Seek Acceptance for Amendment to Warrants
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that it is making an Application to the TSX Venture Exchange for Acceptance of the proposed amendment to the terms of 17,495,472 share purchase warrants (“Warrants”) issued in April, May, and July 2020 in connection with Private Placements completed at that time. Pursuant to Acceptance by the TSXV during 2022, the Expiration date of the Warrants was extended to December 31, 2023. Subject to, and conditional on Acceptance by the TSXV, the Company will amend the Exercise Price of the
May 10, 2023 04:15 pm ET
MedX Announces Appointment of Stephen Lockyer as CEO
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Stephen Lockyer has been appointed as Chief Executive Officer, effective immediately, in place of Naman Damaghlatrous, who has resigned both as an officer and director of the Company.
Apr 25, 2023 04:15 pm ET
MedX Health Announces Board Changes
MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce changes to its Board of Directors.
Apr 18, 2023 07:40 am ET
MedX Health and PharmaChoice Announce Agreement to Launch MedX Teledermatology Screening Platform Across Canada
MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce a Memorandum of Understanding for the launch of a new commercialization pilot project (the "Pilot Project”) with PharmaChoice Canada (“PharmaChoice”), one of Canada’s fastest-growing pharmacy groups, with more than 1000 independent pharmacy owners and operators across its PharmaChoice and RxHealthMed brands.
Apr 03, 2023 11:52 pm ET
TSX Venture Exchange Stock Maintenance Bulletins
VANCOUVER, BC, April 3, 2023 /CNW/ -
Mar 20, 2023 04:53 pm ET
MedX Health Announces Final Closing of Secured Convertible Debenture Financing
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that it has completed the Final Closing of Secured Convertible Debentures previously announced in its Press Release dated January 30, 2023.
Feb 15, 2023 05:24 pm ET
MedX Announces First Closing of Secured Convertible Debenture Financing
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that it has completed the First Closing of Secured Convertible Debentures previously announced in its Press Release dated January 30, 2023.
Jan 30, 2023 04:35 pm ET
MedX Announces Proposed Secured Convertible Debenture Financing
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that it is proposing to complete a private placement financing to raise up to $1.5 million by issuance of one or more Secured Convertible Debentures.
Jan 06, 2023 04:17 pm ET
MedX Announces Closing of Secured Convertible Debenture Financing
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that, further to its Press Release dated November 18, 2022, it has closed a private placement financing to raise $1.5 million by issuance of a Secured Convertible Debenture (“Convertible Debenture”).
Nov 18, 2022 04:38 pm ET
MedX Announces Proposed Secured Convertible Debenture Financing
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that it is proposing to complete a private placement financing to raise up to $1.5 million by issuance of a Secured Convertible Debenture.
Oct 24, 2022 05:51 pm ET
MedX Announces Final Closing of Issuance of Series III Convertible Loan Notes
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that on October 21, 2022 it finalized Closing of the private placement of Series III Convertible Loan Notes (“Series III Notes”) which, since it was first announced, has comprised issuance of a total of 22 Series III Notes, to raise a total of $1.1 Million.
Sep 09, 2022 08:35 am ET
MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that, in connection with the Private Placement (the “Financing”), and further to the $250,000 first tranche closing of which was announced in its Press Release dated July 14, 2022, and its Press Release dated August 11, 2022 announcing application for extension of Price Protection, it has closed on further subscriptions for $350,000, for issuance of seven more Convertible Notes. No Cash Commissions or Agent’s Warrants were paid or issued in relation to those seven Convertible Notes. Securities i
Aug 11, 2022 04:15 pm ET
MedX Health Applies for Extension of Price Protection for Private Placement Convertible Loan Note Financing
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that, in connection with the Private Placement (the “Financing”), the $250,000 first tranche closing of which was announced in its Press Release dated July 14, 2022, it has applied to the TSX Venture Exchange for an extension of a further 30 days price protection in order to complete subscriptions for up to a total of $4 million. Further Closings, will be subject to receipt of subscriptions and a number of other conditions, including, without limitation, the
Aug 02, 2022 04:30 pm ET
MedX Health Strengthens Its Senior Management Team
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Tarek El Hoss has been appointed as the Company’s Vice President, Market Development and Sales. Mr. El Hoss will oversee strategic global growth initiatives and will be responsible for the deployment of market development strategies to impact immediate revenue generation and growth.
Jul 26, 2022 05:35 pm ET
MedX Health Corp. Announces the Launch of Its Dermatological Screening Services in Newfoundland and Labrador
MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, and Central Health are pleased to announce the launch of MedX’s DermSecure® skin screening services in Newfoundland and Labrador.
Jul 14, 2022 04:36 pm ET
MedX Announces Closing of First Tranche of Non-Brokered Private Placement of Convertible Loan Notes and Also Announces Application for Warrant Extension
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that it has closed on the First tranche, of $250,000, of the non-brokered Private Placement announced in its Press Release of June 30, 2022.
Jul 07, 2022 08:48 am ET
MedX Announces Amendment to the Terms of Previously Announced Non-Brokered Private Placement of Series III Convertible Loan Notes
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that it has made an amendment to the terms of the non-brokered Private Placement previously announced in its News Release dated June 30, 2022. The private placement is being offered to accredited investors to raise up to $4 million by issuance of up to 80 Series III Convertible Loan Notes, each with a face value of $50,000 (“Series III Convertible Notes”).
Jun 30, 2022 08:01 am ET
MedX Announces Non-Brokered Private Placement of Series III Convertible Loan Notes to Raise Up To $4 million and Also Grant of Stock Options
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that it is proposing a non-brokered Private Placement to accredited investors of up to $4 million by issuance of up to 80 Series III Convertible Loan Notes, each with a face value of $50,000 (“Series III Convertible Notes”).
Jun 21, 2022 08:33 am ET
MedX Announces Final Acceptance of Issuance of Series II Convertible Loan Notes
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that it has received final Acceptance from the TSX Venture Exchange in respect of the Closing of the placement of Series II Convertible Notes that took place on March 21, 2022, and which comprised issuance of 20 Series II Convertible Notes, and raised a total of $1 Million. That Closing was originally announced in the Company’s Press Release dated March 22, 2022.
Jun 14, 2022 08:10 am ET
MedX Health Adds New Board Member
Mr. Demaghlatrous, who was named CEO on March 23, 2022, has over 20 years of healthcare and pharmaceutical industry experience, previously building international market development strategies and distribution networks for Medtronic, Johnson & Johnson, and Atfal Pharma. He joined MedX in 2021 as Managing Director, Europe, Middle East & Africa Operations, and has since been instrumental in developing and expanding the Company’s global market opportunities and establishing distribution partnerships and adoption of MedX’s DermSecure® Screening Platform in Europe, the Middle East, and No
May 30, 2022 06:40 pm ET
MedX Health Corp. Announces First Quarter 2022 Results
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, announced its financial results for the three-months ended March 31, 2022, which are also available on SEDAR (www.sedar.com).
May 12, 2022 04:57 pm ET
MedX Health Applies for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) has announced that, in connection with the Private Placement ( the “Financing”) originally announced in its press release dated March 1, 2022, and the first Closing of $1 million of the Financing announced in its press release dated March 22, 2022, and the extension of Price Protection announced in its press release dated April 13, 2022, it has applied to the TSX Venture Exchange for a further, and Final, extension of 30 days price protection in order to complete subscriptions for up to a further $3 million. Closing o
May 12, 2022 08:05 am ET
MedX Health Corp. Signs Commercial Distribution Agreement with Makromed/Arhan Global A.Ş to Launch MedX's Teledermatology Screening Platform in Turkey
MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX) is pleased to announce the signing of a commercial distribution agreement with Makromed/Arhan Global A.Ş ("Makromed") following the conclusion of its successful paid pilot project. In conjunction with signing the agreement, Makromed has committed to an initial 60-unit order for 2022, with an immediate order of 40 units and an option for 20 more units to be confirmed by October 2022.
May 02, 2022 08:18 pm ET
MedX Health Corp. Announces 2021 Year End Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the year ended December 31, 2021, which are also available on SEDAR (www.sedar.com).
Apr 13, 2022 08:00 am ET
MedX Health Applies for Extension of Price Protection for Private Placement Convertible Loan Note Financing
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that in connection with the Private Placement ( the “Financing”) originally announced in its press release dated March 1, 2022, and the first Closing of $1 million of the Financing announced in its press release dated March 22, 2022, it has applied to the TSX Venture Exchange for an extension of a further 30 days price protection in order to complete subscriptions for up to a further $3 million. Further Closings will be subject to receipt of subscriptions and a number of other conditions, includ
Apr 04, 2022 08:23 am ET
MedX Health Corp. Signs Commercial Distribution Agreement With Vitamed Biomedical to Launch MedX’s Teledermatology Screening Platform in Italy
MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce the signing of a commercial distribution agreement with Vitamed Biomedical s.r.l. (“Vitamed”) following the conclusion of its successful pilot project. In conjunction with signing the agreement, Vitamed has committed to an initial 60-unit order for 2022; an immediate order of 40 units, with an option for 20 more units to be confirmed by September, 2022.
Mar 23, 2022 08:32 am ET
MedX Health Appoints New CEO
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Naman Demaghlatrous has been appointed as the Company’s President and Chief Executive Officer, effective immediately. The Company wishes to thank Sylvain Desjeans for his service and looks forward to continuing to work with him as he remains a director of MedX.
Mar 22, 2022 08:24 am ET
MedX Announces First Closing of $1 Million in Non-Brokered Private Placement of Convertible Loan Notes and Warrant Extension
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that it has closed on the First tranche, of $1 million, of the non-brokered Private Placement announced in its Press Release of March 1, 2022.
Mar 14, 2022 02:50 pm ET
MedX Announces Intention to Seek Acceptance for Extension of Warrants
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is making an Application to the TSX-V for Acceptance of the proposed extension of the Expiration Dates of a series of Warrants issued in April/May, 2020 in connection with a Private Placement completed at that time. Subject to, and conditional on Acceptance by the TSX-V, the Company will extend the Expiration dates of a total of 14,995,472 share purchase warrants (“Warrants”) and 569,760 brokers warrants (“Brokers Warrants”) from their respective Expiration dates of
Mar 02, 2022 09:14 am ET
MedX Health and Health Partners Announce Agreement to Launch MedX’s Teledermatology Screening Platform in the United Kingdom
MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce a Memorandum of Understanding (“MOU”) and the launch of a new commercialization pilot project with Health Partners (OH) Limited, a well-respected, privately-owned corporate health, treatment and primary care services company in the United Kingdom. Serving a broad client base comprising corporates, government agencies, insurers, health trusts, pension funds and individuals, Health Partners (“HP”) employs 700+ people with telehealth, mobile and on-site operations acro
Mar 01, 2022 08:21 am ET
MedX Announces Non-Brokered Private Placement of Convertible Loan Notes
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is proposing a non-brokered Private Placement to accredited investors of up to $4 million by issuance of up to 80 Convertible Loan Notes, each with a face value of $50,000 (“Convertible Notes”).
Feb 17, 2022 09:22 am ET
MedX Health Announces Clinic and Mobile Dermatological Screening Services Partnership in New Brunswick
MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce a new regional partnership in New Brunswick, Canada. MedX Health has partnered with Dr. Jeff Sheppard in Saint John, New Brunswick to offer MedX’s DermSecure® skin screening services in both Saint John and in underserved smaller communities in New Brunswick. The services will be offered both in established clinics and as a mobile service on a regular schedule to smaller communities in New Brunswick, and expanding to other provinces in Atlantic Canada.
Feb 16, 2022 04:23 pm ET
Don't Miss Upcoming PBA a Noon Webinars; MedX Health, Val-d'Or Mining, and Bonterra Resources
Montreal, Quebec--(Newsfile Corp. - February 16, 2022) - PBA ("PBA" or "Paul Benwell & Associates") is pleased to announce that it will be virtually hosting MedX Health Corp. (TSXV: MDX), Val-d'Or Mining Corporation (TSXV: VZZ), and Bonterra Resources (TSXV: BTR), for their signature PBA à Noon webinar.
Jan 27, 2022 08:30 am ET
MedX Health Announces Addition of Two New Screening Services Locations in Ottawa
Teledermatology company MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX) is pleased to announce the launch of MedX Screening Services to be offered at two locations in Ottawa, Canada – ProMed Pharmacy, an independent, pharmacist owned pharmacy enterprise, and Dura Wellness Clinic a retail, clinical focused esthetic services group. Both locations will now offer MedX scanning services and accept walk-in patients.
Jan 20, 2022 08:35 am ET
MedX Health Corp. Launches DermSecure Screening Services with Medicure Clinic
MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, and the Medicure Clinic ("Medicure" or the “Clinic”) are pleased to announce the launch of MedX Screening Services at Medicure, a physician-owned clinic that also houses a pharmacy. MedX’s scanning services are now available to the Clinic’s roster of 5,000 existing family physician patients as well as walk-in patients through the on-site pharmacy.
Jan 17, 2022 04:23 pm ET
MedX Health Corp. Announces Addition of Three New Screening Services Locations Across Ontario
MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce that MedX's leading-edge DermSecure® screening platform services are being offered in Empower's (CSE: CBDT | OTCQB: EPWCF) The Medi-Collective ("TMC") locations across Ontario, Canada.
Dec 06, 2021 02:36 pm ET
MedX Health to Present at the SNN Network Canada Virtual Event December 7 – 9, 2021
MedX Health Corp. (TSXV: MDX) (“MedX” or the “Company”), a global leader in teledermatology, is pleased to announce its participation in the SNN Network Canada Virtual Event, taking place virtually December 7th – 9th, 2021.
Nov 30, 2021 04:25 pm ET
MedX Health Corp. and London Medical Laboratory Ltd. Announce Commercialization Pilot of World-Class Teledermatology Screening Platform in the United Kingdom
Teledermatology company MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) and London Medical Laboratory Ltd. ("LML") are pleased to announce a Memorandum of Understanding on a commercialization pilot and distribution agreement for MedX’s leading-edge DermSecure® Screening Platform in the United Kingdom (UK).
Nov 29, 2021 05:59 pm ET
MedX Health Corp. Announces Third Quarter 2021 Results
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) announced its results for the three and nine months ended September 30, 2021, which are also available on SEDAR (www.sedar.com).
Nov 22, 2021 08:30 am ET
MedX Health Corp. Consulting with Medical Advisory Boards Across North America
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) recently convened Medical Advisory Boards of leading dermatologists across Canada and the United States to explore clinical application opportunities for its image capture technology, SIAscopy® and patient management system, DermSecure®.
Nov 18, 2021 04:53 pm ET
MedX Health Corp. and Al Zahrawi Medical Supplies LLC Announce Distribution Agreement for Leading-Edge Teledermatology Screening Platform in United Arab Emirates
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) and Al Zahrawi Medical Supplies LLC ("Al Zahrawi") are pleased to announce a Memorandum of Understanding between the companies on a two-phase commercialization pilot and distribution agreement for MedX’s leading-edge DermSecure® Screening Platform at select United Arab Emirates (“UAE”) oncology and dermatology clinics beginning this month.
Nov 17, 2021 04:15 pm ET
MedX Health Corp. Announces Inaugural Clinical Trial of Leading-Edge Teledermatology Screening Platform in Turkey
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce an inaugural clinical trial of its leading-edge DermSecure® Screening Platform at three university hospitals across Turkey in early 2022.
Nov 16, 2021 04:22 pm ET
MedX Health Corp. and Makromed/Arhan Global Announce Distribution Agreement for Leading-Edge Teledermatology Screening Platform in Turkey
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) and Makromed/Arhan Global A.Ş ("Makromed/Arhan") are pleased to announce a Memorandum of Understanding between the companies on a distribution agreement for MedX’s leading-edge DermSecure® Screening Platform, facilitating a clinical trial of the technology at three university hospitals across Turkey in early 2022.
Oct 21, 2021 04:19 pm ET
MedX Health Corp. Appoints Lesley Bourget as Chief Financial Officer
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that seasoned pharmaceutical finance executive Lesley Bourget has been appointed as the Company’s Chief Financial Officer (“CFO”), effective November 8th, 2021.
Sep 29, 2021 05:56 pm ET
MedX to Present at Benzinga Healthcare Conference on September 30th
Mississauga, Ontario--(Newsfile Corp. - September 29, 2021) - MedX Health Corp. (TSXV: MDX) ("MedX" or the "Company"), a global leader in teledermatology, is pleased to announce its participation in the Benzinga Healthcare Small Cap Conference (the "Conference"), taking place virtually on Thursday, September 30th at 4:40 PM ET.
Sep 27, 2021 08:00 am ET
MedX Health Corp. and Vitamed Biomedical s.r.l. to Pilot Leading-Edge Teledermatology Screening Platform in Italy
MedX Health Corp. (“MedX” or the “Company”) (MDX - TSXV) and Vitamed Biomedical s.r.l. ("Vitamed") are pleased to announce a Memorandum of Understanding between the companies to pilot MedX’s leading-edge DermSecure® Screening Platform at select pharmacies and general practitioner (GP) clinics in Italy this October.
Sep 20, 2021 08:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the September 16th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live executive presentations and...
Sep 15, 2021 02:42 pm ET
MedX to Present at Life Sciences Investor Forum on September 16th
MedX Health Corp. (TSXV: MDX) (“MedX” or the “Company”), a global leader in teledermatology, is pleased to announce its participation in the Life Sciences Investor Forum, taking place virtually on Thursday, September 16 at 1:00 PM EST. Mike...
Sep 10, 2021 08:35 am ET
Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Aug 24, 2021 06:00 pm ET
MedX Health Corp. Announces Second Quarter 2021 Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announced its results for the three and six-months ended June 30, 2021, which are also available on SEDAR (www.sedar.com).
Aug 23, 2021 07:00 pm ET
MedX Announces Board Changes
MedX Health Corp. (“MedX” or the “Company”) (MDX – TSXV), announces that at the Annual and Special General Meeting of shareholders held on August 16, 2021, Rob von der Porten retired as a director, thus creating a vacancy on the Board. Mr. von der Porten had been not only Chairman of the Board, but also acting as Chief Executive Officer during the last fifteen-month period that MedX was conducting a search for a new CEO. Ken McKay has been appointed as Chairman of the Board. In addition, Sylvain Desjeans, recently promoted to President and CEO of MedX, has been appointed to the B
Aug 12, 2021 08:00 am ET
MedX Health Corp. Appoints Sylvain Desjeans as Chief Executive Officer
MedX Health Corporation (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Sylvain Desjeans has been appointed as the Company’s President and Chief Executive Officer, effective immediately.
Jun 15, 2021 09:30 pm ET
MedX Announces Issuance of Shares as Compensation for Consulting Services
MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announces that, further to Acceptance from the TSX Venture Exchange, it has issued 360,000 common shares at a deemed issue price of $0.20 per share, representing a total consideration of $72,000, as compensation for consulting services rendered. The shares were issued pursuant to the prospectus exemption contained in NI 45-106 s. 2.24; subject to the criteria contained in NI 45-102 s. 2.6(3) being met, the shares are not subject to any restrictive hold period.
Jun 15, 2021 05:18 pm ET
MedX Health Corp. and VidaCeuticals Health Products Inc. Announce North American Distribution Partnership
MedX Health Corporation (“MedX” or the “Company”) (TSX-V: MDX) a global leader in teledermatology, is pleased to announce a distribution agreement with VidaCeuticals Health Products Inc. that will see MedX’s integrated skin assessment teledermatology platform offered at four clinics in Ontario beginning in late June, with plans for a broader market roll-out in Canada and the United States later this year. The initial four clinics will be located in London, Ottawa, Port Elgin and Sarnia.
Jun 10, 2021 11:54 am ET
MedX Announces Closing of $500,000 Non-brokered Private Placement of Convertible Debenture Loan Notes to Redeem Existing Secured Loan and Finalization of Previously Announced Non-brokered Private Plac
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that, further to the Press Release dated June 2, 2021, and pursuant to Conditional Acceptance of the TSX-V, it has today closed an agreement to redeem an existing $500,000 secured loan by way of a non-brokered Private Placement of 10 Convertible Debenture Loan Notes, each with a face value of $50,000 (“Convertible Notes”) to the same accredited investor. The Convertible Notes, which have similar terms to the Loan Notes issued by the Company in February, 2021, bear interest at 6% per year, payable Quarterly, and wi
Jun 02, 2021 09:49 pm ET
MedX Announces $500,000 Non-Brokered Private Placement of Convertible Debenture Loan Notes to Redeem Existing Secured Loan
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that, subject to TSX-V Acceptance, it has entered into an agreement to redeem an existing $500,000 secured loan by way of a non-brokered Private Placement of 10 Convertible Debenture Loan Notes, each with a face value of $50,000 (“Convertible Notes”) to the same accredited investor. The Convertible Notes, which have similar terms to the Loan Notes issued by the Company in February, 2021, bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2023 (the “Maturity Date”). The Convertible Not
May 31, 2021 06:00 pm ET
MedX Health Corp. Announces First Quarter 2021 Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three-months ended March 31, 2021, which are also available on SEDAR (www.sedar.com).
May 14, 2021 05:00 pm ET
MedX Health Corp. Announces Non-Brokered Private Placement and Closing of First Tranche
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it has received Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 13,888,888 units at $0.18 per unit (“Unit”), to raise up to $2,500,000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.25, exercisable for a period of two years from the date of issue. Closing of the Placement, which will take place in tran
May 05, 2021 08:00 am ET
MedX Health Corp. Names Health-Care Leader Sylvain Desjeans as Chief Revenue Officer
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce the appointment of Sylvain Desjeans as Chief Revenue Officer. With more than 30 years of health-care industry experience, Mr. Desjeans is a seasoned leader who has successfully implemented and led large-scale strategic growth plans and global product licensing initiatives for international pharmaceutical and medical companies. He comes to MedX from tenures as Country Manager (Canada) for Aspen Pharmacare and senior leadership positions at Accucaps Industries Limited and Biovail Pharmaceuticals.
Apr 28, 2021 10:56 pm ET
MedX Health Corp. Announces 2020 Year End Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the year ended December 31, 2020, which are also available on SEDAR (www.sedar.com).
Apr 20, 2021 12:10 pm ET
MedX Health to Present at the Planet MicroCap Virtual Event on April 22, 2021
MedX Health Corp. (TSXV: MDX) (“MedX” or the “Company”), a global leader in teledermatology, will present at the Planet MicroCap Showcase: VIRTUAL on Thursday, April 22nd at 12:00 PM EDT.
Mar 12, 2021 05:30 pm ET
MedX Health Corp. Announces Retirement of Board Members
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX), a global leader in teledermatology, announces that two of its long-standing directors have announced their intention to retire from the Board. Gary Van Nest joined the Board in November 2001 and was Chairman from 2008 until 2018. David Breukelman joined the Board in November 2015.
Mar 10, 2021 08:40 am ET
MedX Health Corp. and Empower Clinics Inc. to Pilot World-Class Teledermatology Screening Platform at Select Ontario Integrated Health Centres
MedX Health Corporation (“MedX” or the “Company”) (TSX-V: MDX) and Empower Clinics Inc. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) ("Empower" or the "Company") are pleased to announce a Memorandum of Understanding between the companies to pilot MedX’s leading-edge DermSecure™ Screening Platform at two select Empower Clinics in Ontario with plans for a broader market roll-out pending the pilot’s completion.
Mar 02, 2021 08:00 am ET
MedX Health Corp. Announces the Appointment of a Sales and Marketing Director for Europe, Middle East, Africa (EMEA)
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX), a global leader in teledermatology, is pleased to announce the appointment of veteran healthcare industry executive Paul Karam as Sales and Marketing Director, Europe, Middle East & Africa ("EMEA"), effective immediately. Mr. Karam will be reporting to the Managing Director for the EMEA region and strengthening the MedX global footprint in general and EMEA presence in particular.
Feb 25, 2021 08:00 am ET
MedX Announces Final Closing of $4 Million Convertible Debenture Loan Notes Non-brokered Private Placement
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it has closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes, each with a face value of $50,000 (“Convertible Notes”), as originally announced in its Press Release dated January 25, 2021. Previous Closings were announced earlier in February 2021.
Feb 01, 2021 08:00 am ET
MedX Announces Closings of First $2.5 Million of Convertible Debenture Loan Notes, and Anticipates Further Closings up to $1.5 Million
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it has closed on the first $2.5 million of the $4 million Non-brokered Private Placement of Convertible Debenture Loan Notes each with a face value of $50,000 (“Convertible Notes”) as originally announced in its Press Release dated January 25, 2021. On January 27 and 28, 2021, there were closings of 40 and 10 Convertible Notes respectively, raising gross proceeds of $2.5 million. The Convertible Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2023 (the
Jan 25, 2021 08:00 am ET
MedX Announces Non-Brokered Private Placement of Convertible Debenture Loan Notes
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is proposing a non-brokered Private Placement to accredited investors of up to $4 million by issuance of up to 80 Convertible Debenture Loan Notes, each with a face value of $50,000 (“Convertible Notes”). The Convertible Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2023 (the “Maturity Date”). The Convertible Notes may be converted, at the option of the Holder, into units at $0.14 per unit (“Unit”) at any time until the Maturity Date. Each Unit wil
Jan 04, 2021 08:00 pm ET
MedX Issues Shares Related to Debt Settlement Agreement
MedX Health Corp. (“MedX”) (TSX-V:MDX) is pleased to announce that effective December 22, 2020, it closed the debt settlement announced in its Press Release dated December 22, 2020, pursuant to which it settled $65,000 of debt owed to an arm’s length professional adviser by issuance of 500,000 common shares. The shares issued on this debt settlement will be restricted from trading for four months from the date of issue.
Dec 31, 2020 03:30 pm ET
MedX Health to Present at the SNN Network Canada Virtual Event on Thursday, January 7, 2021
MISSISSAUGA, ON / ACCESSWIRE / December 31, 2020 / MedX Health Corp. (TSXV:MDX)("MedX" or "the Company"), a global leader in teledermatology, will be presenting at the SNN Network Canada Virtual Event on Thursday, January 7th at 5:00 PM EST. Mike Druhan, President of Dermatology Products & Services, will host the presentation and answer investors' questions.
Dec 22, 2020 06:30 pm ET
MedX Announces Debt Settlement Agreement
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that the Company has agreed to settle an amount of $65,000 owing to a professional advisor, subject to all relevant consents and approvals, by issuing 500,000 common shares to the vendor, at a price of $0.13 per share. Regulatory and other consents will include acceptance from the TSX Venture Exchange.
Dec 21, 2020 08:00 am ET
Dr. Trevor Champagne Appointed Chair of MedX Health Corp.’s Medical Advisory Board
MedX Health Corporation ("MedX" or the "Company") (TSX-V: MDX), is pleased to announce the appointment of Dr. Trevor Champagne as Chair of the Company's Medical Advisory Board. A member of the Advisory Board since 2018—among other distinguished members and world-class dermatologists Dr. Daniel Siegel, Dr. Per Hall, Dr. Joe Walls, and Dr. Dennis Reich—Dr. Champagne has helped position MedX as a leader in teledermatology.
Dec 14, 2020 06:24 pm ET
MedX Health Corp. Announces the Rollout of DermSecure® in the Netherlands
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX), a global leader in teledermatology, announces that it has begun the rollout of DermSecure®, MedX's skin screening telemedicine platform, across the Netherlands in partnership with national telehealth leader The Netherlands Institute for Prevention and Health ("IVPG").
Nov 30, 2020 08:00 am ET
MedX Health Corp. Announces Third Quarter 2020 Financial Results and Grant of Stock Options
MedX Health Corp. (“MedX” or “Company”) (TSX-V: MDX) announced its results for the three and nine-months ended September 30, 2020, which are also available on SEDAR (www.sedar.com).
Nov 12, 2020 07:00 am ET
MedX Health to Present at the Fall Investor Summit on November 17th
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / MedX Health Corp. ("MedX", or the "Company") (TSXV:MDX), a Company focused on becoming the leader in teledermatology, will be presenting at this year's virtual Fall Investor Summit on Tuesday, November 17th at 4:00PM (EST) / 1:00PM (PST), and will host virtual one-on-one meetings with interested investors throughout the conference, which runs November 16 -18. To register, or to schedule a virtual one-on-one meeting, visit https://investorsummitgroup.com
Oct 28, 2020 05:25 pm ET
MedX Health Corp. Expands North American Clinic Sales
MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX), the global leader in teledermatology, announces that it has completed a sales agency agreement with the Ziemer Professional Corporation. Mr. Paul Ziemer, President, has 20 years of experience in medical device sales and medical clinic operations. “I have been working with the MedX team to develop a go-to market strategy and I am pleased to announce that the first six clinics will roll-out in the next three weeks with installations across Ontario and Saskatchewan. Preparations are already in place for additional installations in Canada an
Oct 15, 2020 04:12 pm ET
 MedX Health Corp. Adds Health Care Expertise to Its Board of Directors
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a Company focused on becoming the global leader in teledermatology, announces that it has appointed Anthony Milonas and Wayne Cockburn as Directors of the Company, effective immediately. Mr. Milonas and Mr. Cockburn have extensive senior management experience working with medical device and health care growth-stage companies, both nationally and internationally.
Sep 25, 2020 08:00 pm ET
MedX Health Corp. Announces Second Quarter 2020 Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three and six-months ended June 30, 2020, which are also available on SEDAR (www.sedar.com).
Sep 21, 2020 08:00 am ET
MedX Health Corp. Bolsters Global Footprint and Adds Renowned Skin Care Expert to Senior Leadership Team
MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa (“EMEA”), effective immediately. Additionally, Chantal Ward, RN has taken a permanent position with the Company as Director, Dermatological Services.
Sep 09, 2020 08:00 am ET
MedX Health Corp. Announces Management Changes and Increased Focus on SIAscopy™ on DermSecure™
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced that it has completed management changes to enhance its focus on its dermatological services and products (“DSP”) including DermSecure™ and SIAscopy™.
Aug 27, 2020 07:00 pm ET
MedX Health Corp. Announces Postponement of the Release of Second Quarter Interim Financial Statements and Related Disclosure Due to COVID-19 Related Delays
MedX Health Corp. (MDX: TSXV) (“the Company”), announces that there will be a delay in the filing of its Interim Financial Statements and accompanying Management’s Discussion and Analysis, and related CEO and CFO certifications for the Second Quarter ended June 30, 2020 (collectively "Interim Filings") due to COVID-19 related delays.
Aug 15, 2020 02:46 pm ET
MedX Announces Issuance of Shares in Connection with Advertising Services Agreement
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that pursuant the agreement for an online marketing and awareness program through AGORACOM, that was announced in a Press Release dated June 1, 2020, it has settled the second payment to AGORACOM, in the amount of $13,560, by issuance on August 12, 2020, of 104,307 shares at an issue price of $0.13 per share. The issue price of the shares was determined by using the undiscounted closing price of the Shares of the Company on the TSX Venture Exchange on August 11, 2020, being the last trading day before the date of issuance. The shares were issue
Aug 04, 2020 08:21 pm ET
MedX Health Corp. Announces Closing of Non-Brokered Private Placement
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 16,666,666 units at $0.12 per unit (“Unit”), to raise up to $2,000,000, the closing of a first tranche of that placement has taken place on July 31, 2020, for a total of 2,600,000 units, raising a total of $312,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of
Jul 14, 2020 09:48 pm ET
MedX Health Corp. Announces First Quarter 2020 Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three-months ended March 31, 2020, which are also available on SEDAR (www.sedar.com).
Jun 30, 2020 09:00 pm ET
MedX Health Corp. Provides Update on the Release of Its First Quarter 2020 Interim Financial Statements and Related Disclosures, and Retirement of a Director
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) provides an update on the filing of its Interim Financial Statements and related Disclosures for the First Quarter of fiscal 2020 (the “Interim Disclosures”) which was delayed owing to COVID-19 related issues. As previously announced in its Press Release dated May 27, 2020, the Company anticipates that the Interim Disclosures will be filed by July 13, 2020.
Jun 18, 2020 08:00 am ET
MedX Announces Executive Changes
MedX Health Corp. (“MedX”) (MDX – TSXV), announced today that President and CEO Scott Spearn has resigned for family reasons, effective immediately. Rob von der Porten, Chairman of the Board, has been named interim Executive Chair. Mr. Spearn will also be retiring from the Board at or prior to the next AGM. The Board will commence a search for suitable candidates to take on the CEO position.
Jun 15, 2020 07:00 am ET
MedX Health Signs Exclusive Distribution Agreement to Launch SIAscopy on DermSecure™ in Mexico
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed an Exclusive Distribution Agreement with EMC LABS, S.A.P.I. DE C.V., operating as MedX Mexico (“MedX Mexico”), which plans to launch an aggressive ease-of-access skin scanning/assessment program throughout Mexico, using MedX’s SIAscopy on DermSecure™ Telemedicine platform. The exclusivity was granted to MedX Mexico based on its strong connections within the Mexican marketplace as well as its upfront commitment to cover the application for regulatory approval in Mexico and all marketing costs, and the large-scale
Jun 12, 2020 05:00 pm ET
MedX Health Corp. Announces 2019 Year End Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the year ended December 31, 2019, which are also available on SEDAR (www.sedar.com).
Jun 02, 2020 10:05 pm ET
MedX announces issuance of shares in connection with Advertising Services Agreement
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that pursuant to the agreement for an online marketing and awareness program through AGORACOM, that was announced in the Press Release dated June 1, 2020, it has settled the first payment to AGORACOM, in the amount of 12,000 plus HST, or $13,560, by issuance on June 1, 2020, of 90,400 shares at an issue price of $0.15 per share. The issue price of the shares was determined by using the closing price of the Shares of the Company on the TSX Venture Exchange on May 29, 2020, being the last trading day before the date of issuance. The shares were i
Jun 01, 2020 05:44 pm ET
MedX Launches AGORACOM Online Marketing and Awareness Program
MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce that it is implementing an online marketing and awareness program through AGORACOM.
May 28, 2020 12:10 pm ET
MedX Health Corp. Appoints Nick Hoffman, Medical Imaging and Equipment Executive, as Director Business Development
MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce the appointment of medical equipment industry executive Nick Hoffman as Director, Business Development, effective immediately. Mr. Hoffman will be working with the MedX team in managing customer acquisition and support initiatives as the Company commercializes and begins an aggressive installation phase for its SIAscopy on DermSecure™ telemedicine platform.
May 27, 2020 08:39 pm ET
MedX Health Corp. provides update on the release of its Annual Financial Statements and related Disclosures for fiscal 2019 and postponement of release of its First Quarter 2020 Interim Financial Stat
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces an update on the filing of its Annual Financial Statements and related Disclosures (the “Annual Disclosures”) for the year ended December 31, 2019, following the earlier announcement in its Press Release dated April 28, 2020, that filing of the Annual Disclosures would be delayed due to COVID-19 related delays. The Company is continuing to work diligently and expeditiously with its auditors, and anticipates that the Annual Disclosures will be filed by June 12, 2020, as previously indicated.
May 22, 2020 08:30 am ET
MedX Health Corp. Appoints Veteran Healthcare Industry Executive Damon Goodwin as Global Director of Sales
MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce the appointment of healthcare industry executive Damon Goodwin as Global Director of Sales, effective immediately. Mr. Goodwin will play an integral part in MedX’s revenue growth by building global partnerships for MedX’s skin assessment telemedicine technology. Initially supporting the roll out and expansions in Mexico, Brazil and the USA, he will also be responsible for securing joint ventures & partnerships around the world.
May 20, 2020 10:21 pm ET
MedX Health Corp. Confirms Details of Closings of Non-Brokered Private Placements
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) confirms the precise specifics of the series of closings of non-brokered private placements made since January 30, 2020, announced in recent Press Releases by the Company. The following Table sets out the particulars of the dates of each closing, the number of units issued and the amount raised on each closing, together with details of Agent’s Warrants and cash commissions paid to Agents at each closing.
May 19, 2020 08:00 am ET
MedX Health Corp. Announces Final Closing of $3 Million Non-Brokered Private Placement
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces the closing on May 13, 2020 of the final tranche of a previously announced private placement. With this closing, MedX has raised gross proceeds totalling $3,112,753 since January 30, 2020. “This marks the successful achievement, indeed over-achievement of the target, set in January 2020 to raise $3.0 million to finance the development and expansion of MedX’s complete end-to-end telehealth solution focused on Dermatology. The funding will allow MedX to hire key sales and operational personnel required to expand int
Apr 28, 2020 08:39 pm ET
MedX Health Corp. Announces Closing of Initial Tranches of Non-Brokered Private Placement and Announces That Due to COVID-19 Delays It Will Postpone the Release of Its Annual Financial Statements and
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 25,000,000 units at $0.12 per unit (“Unit”), to raise up to $3,000,000 that was announced on March 6, 2020, the closing of two tranches of that placement have taken place, the first on April 22, and the second on April 27, 2020, for a total of 9,908,006 units, raising a total of $1,188,960. Closings of further tranches of this non-brokered placement are anticipat
Apr 16, 2020 10:00 pm ET
MedX Health Corp. Announces Proposed Extension of Non-Brokered Private Placement Offering
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced today that, subject to acceptance by the TSX-V the ultimate Closing Date for the non-brokered Private Placement of up to $2.5 million, which was previously announced on March 6, 2020, will be extended by up to 30 days. The Company has already received Conditional Acceptance for the placement from the TSX-V, but closings have been delayed primarily as a result of Government-imposed restrictions in response to the COVID-19 Pandemic. The proposed placement, to accredited investors, is for the placement of up to 20,83
Apr 02, 2020 08:30 am ET
MedX Receives MDSAP Certification, The Highest Regulatory Standard in the Medical Device Manufacturing Industry
MedX Health Corp. (“MedX”) (TSX-V: MDX) a leading medical device and software company focused on skin assessment in identifying suspicious moles and lesions by utilizing its SIAscopy optical scanning technology coupled with its SIAscopy on DermSecure™ telemedicine platform, is pleased to announce that it has achieved a recommendation for continued certification on successful completion of an audit under the Medical Device Single Audit Program (“MDSAP”).
Mar 17, 2020 01:09 pm ET
MedX Receives Regulatory Approval in Brazil
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has received regulatory approval to market and sell its SIAscopy on DermSecure TM skin assessment platform in Brazil. “MedX has worked seamlessly with its Brazilian distribution partners, MedX Brasil and Oneway Diagnostica to ensure we were able to complete this important certification from ANVISA, Brazil’s regulatory authority,” commented Scott Spearn, President & CEO of MedX. “We had the support of the Brazilian Dermatological community in this process, and we are very appreciative of the efforts and professionalism of our
Mar 06, 2020 04:00 pm ET
MedX Health Corp. Announces Closing of Non-Brokered Private Placement and Debt Settlement and Announces a New Non-Brokered Private Placement Offering
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 25,000,000 units at $0.12 per unit (“Unit”), to raise up to $3,000,000 that was announced on January 30, 2020, and the closing of the first tranche of that placement, of 1,485,000 units, raising $178,200, on January 30, 2020, two further closings have taken place, on March 4, 2020, of 7,459,139 units, raising $895,096, and on March 5, 2020, of 2,000,000 units, ra
Mar 03, 2020 11:06 pm ET
MedX Health Corp. Announces Proposed Debt Settlement
MedX Health Corp. (TSX-V:MDX), announces that it has entered into an agreement to settle $372,071 of debt owed to an arm’s length trade creditor, subject to all relevant consents and approvals. Under the Debt Settlement Agreement, $372,071 of trade debt will be settled by the issuance of 3,103,878 units (“Unit(s)”) at a price of $0.12 per Unit. Each Unit comprises one fully paid common share and one share purchase warrant, exercisable for a period of two (2) years from the date of issue, to acquire a further common share at the price of $0.20. Regulatory and other consents will i
Jan 30, 2020 08:52 pm ET
MedX Health Corp. Announces Non-Brokered Private Placement and Closing of First Tranche
MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) is pleased to announce that it has received Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 25,000,000 units at $0.12 per unit (“Unit”), to raise up to $3,000,000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. Closing of the Placement, which will take place in tranc
Jan 16, 2020 10:37 pm ET
MedX Health Corp. Announces Granting of Stock Options
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), dedicated to the early detection of skin cancer, announces that a total of 5,990,000 stock options have been granted to directors (2,020,000 options), Officers (1,580,000 options) and employees and consultants (2,390,000 options). The options are all exercisable at the price of $0.17 per share, valid for a period to December 31, 2024, and vest immediately. The Company notes that a total of 7,150,000 stock options previously granted in 2014 expired unexercised on November 26, 2019. At this time there are a total of 21,200,000 opti
Jan 16, 2020 08:00 am ET
MedX Receives Major SIAScopeTM Order for Launch of its DermSecureTM Telemedicine Platform in Brazil
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has received an order for 500 SIAScopeTM units for deployment on its DermSecureTM telemedicine platform from its exclusive Brazilian distributor, representing the single largest order in the Company’s history.
Dec 22, 2019 04:47 pm ET
MedX Health Corp. – Closing of Private Placement
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) notes that with respect to a private placement for which an Initial Closing took place on November 4, 2019, whereby 1,252,000 Units were sold and $150,120 was raised from accredited investors and was announced in a Press Release on November 7, 2019, a further $50,000 was subsequently received, resulting in a Second Closing on November 21, 2019, as envisaged in the Press Release, and the issuance of a further 416,666 Units, which securities will be restricted from trading until March 2, 2022. Each Unit, priced at $0.12, comprises one full
Nov 27, 2019 08:00 am ET
MedX Health Corp. announces Third Quarter 2019 Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three and nine-months ended September 30, 2019, which are also available on SEDAR (www.sedar.com).
Nov 07, 2019 10:01 pm ET
MedX Health Corp. Announces Private Placement Closing
MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an initial Closing of 1,251,000 Units effective November 4, 2019, to raise $150,120 from accredited investors pursuant to a Private Placement Offering announced on November 1, 2019. Each Unit, priced at $0.12, comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at a price of $0.20 during the period up to two years from the closing date of the
Nov 01, 2019 07:00 pm ET
MedX Health Corp. Announces Non-Brokered Private Placement
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it has filed for Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 25,000,000 units at $0.12 per unit (“Unit”), to raise up to $3,000,000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. Closing of the Placement, which will take place in tra
Oct 07, 2019 08:00 am ET
MedX Reports Progress towards DermSecureTM Launch in Brazil
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) experienced strong interest for its SIAscopy on DermSecureTM platform from physicians and dermatologists in Brazil during the recent 74th Congress of the Brazilian Society of Dermatology held in Rio de Janeiro in September 2019. MedX representatives attended to support the large team of sales reps working with the Company’s Brazilian distribution partners at a MedX branded booth at the show, demonstrating the benefits of the platform to the Brazilian dermatologic community in advance of a launch of the product once
Aug 30, 2019 08:30 pm ET
MedX Health Corp. Announces Private Placement Closing
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an initial Closing of 1,286,111 Units on August 29, 2019, to raise $154,333 from accredited investors pursuant to a Private Placement Offering announced on August 28, 2019. Each Unit, priced at $0.12, comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at a price of $0.20 during the period up to two years from the closing date of the placemen
Aug 28, 2019 08:00 pm ET
MedX Health Corp. Announces Non-Brokered Private Placement
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it has obtained Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 16,666,667 units at $0.12 per unit (“Unit”), to raise up to $2,000,000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. Closing of the Placement, whi
Aug 28, 2019 08:00 am ET
MedX Health Corp. Announces Second Quarter 2019 Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three and six-months ended June 30, 2019, which are also available on SEDAR (www.sedar.com).
Jul 16, 2019 09:24 am ET
New Guidelines for Patients Suffering From Mucositis or Oral Ulcerations From Head and Neck Cancer Treatment Can Now Be Effectively Treated With MedX’s Light Therapy Devices
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces it will initiate a targeted marketing campaign following an announcement by a worldwide coalition of researchers and clinicians who have agreed that light therapy is among the most effective interventions for the prevention of oral mucositis and painful ulcers in the mouth and throat resulting from cancer therapy. The Company said this represents a significant sales opportunity in Canada and the United States for MedX’s photobiomodulation therapy devices.
Jun 24, 2019 08:30 am ET
MedX Health Signs Distribution Agreement for Canada, USA and Israel
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed a non-exclusive, performance-based distribution agreement with Group Vida, to distribute MedX’s DermSecureTM skin cancer assessment technology platform in the USA, Canada and Israel.
Jun 17, 2019 07:30 am ET
MedX Health and Sanitas Spain Announce a Large-Scale Skin Cancer Screening Initiative in Spain Using MedX’s DermSecure™ Technology
MedX Health Corp. (“MedX”) (TSX-V:MDX) announces that it has partnered with SANITAS, a specialist in healthcare and well-being services in Spain, to conduct a skin cancer screening initiative. According to recent studies, Spain, with its warm and sunny climate has experienced a 50% increase in skin cancer rates over the last decade. It is the most common form of cancer in women between the age of 25 and 29, followed by breast cancer, and the most common in men between the age of 30 and 35, ahead of lung and colon cancer.
May 30, 2019 08:30 pm ET
MedX Health Corp. Announces First Quarter 2019 Results and Private Placement
MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announced its results for the three-months ended March 31, 2019, which are also available on SEDAR (www.sedar.com).
Apr 30, 2019 08:38 pm ET
MedX Health Corp. Announces 2018 Year End Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announced its results for the year ended December 31, 2018, which are also available on SEDAR (www.sedar.com).
Apr 26, 2019 07:00 pm ET
Apr 09, 2019 08:00 am ET
MedX Health Signs Exclusive Distribution Agreement to Launch DermSecure™ in Brazil, where Skin Cancer is Prevalent
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that it has signed an Exclusive Distribution Agreement with CBD Vida (“Vida”), to launch a comprehensive, ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTM Telemedicine platform.
Mar 04, 2019 08:00 am ET
MedX Health Corp. Announces Private Label Distributor Agreement for Selected Therapeutic Laser Products with Richmar in US
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed an agreement with Richmar, a Compass Health Brands Company, to manufacture and supply selected Private Label Laser and Light products to Richmar for the US rehabilitation market.
Jan 30, 2019 09:00 am ET
MedX Health Signs MOU to Launch DermSecure™ in Brazil
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed a Memorandum of Understanding with CBD Vida LTDA, who plans to launch an ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTM. Telemedicine platform.
Jan 29, 2019 10:15 am ET
Dec 27, 2018 11:35 am ET
MedX Health Announces That Dr. Bruno Battistini, an Accomplished Canadian-Based Health Care Researcher Has Joined Its Medical Advisory Board
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Bruno Battistini, a Canadian-based health care researcher and medical business advisor has joined MedX’s Medical Advisory Board.
Nov 29, 2018 08:00 pm ET
MedX Health Corp. Announces Third Quarter 2018 Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three and nine months ended September 30, 2018, which are also available on SEDAR (www.sedar.com).
Nov 27, 2018 08:00 am ET
MedX Signs MOU to Launch DermSecure™ in the Netherlands
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed a Memorandum of Understanding with a consortium of Dutch companies that will be launching an easy-access skin scanning/assessment program in the Netherlands, using MedX’s SIAscopy and DermSecureTM technologies. The consortium will integrate DermSecureTM with their existing platforms, which includes a suite of software applications used by a large majority of general practitioners in the Netherlands, and will build awareness campaigns through established
Nov 14, 2018 10:25 am ET
MedX Launches Strategic Artificial Intelligence Initiative
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it is initiating the development of an Artificial Intelligence Engine with leading dermatologists and its technology partner, Blanc Labs, that will work in conjunction with its existing DermSecureTM screening platform. MedX has an opportunity to leverage Artificial Intelligence to create a unique assessment support tool allowing Dermatologists to more accurately assess suspicious moles and lesions from remote locations.
Oct 23, 2018 01:46 pm ET
MedX Health Announces That Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany Has Joined Its Medical Advisory Board
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany has agreed to join MedX’s Medical Advisory Board. Dr. Stockfleth was previously the Director of the Skin Cancer Center in Berlin.
Oct 11, 2018 08:00 pm ET
Sep 24, 2018 01:22 pm ET
MedX Health Corp. Announces Board and Executive Changes
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces the following changes to its Board and Executive team, effective immediately. Scott Spearn, who joined the Company as President in April 2018 is taking on the additional role of Chief Executive Officer and is joining the Board of Directors. Rob von der Porten, previously the CEO, has been appointed as Chairman of the Board in place of Gary Van Nest who has retired from that position and remains as a director.
Sep 04, 2018 03:49 pm ET
MedX Launches Its DermSecure™ Telemedicine Platform
MedX Health Corp. (“MedX”) (TSX-V:MDX) announced today that it is launching DermSecure™, its telemedicine platform, in six Ontario clinics. MedX will begin rolling out DermSecure™ across Ontario and subsequently Canada while finalizing its introduction into a number of international markets. It is currently working on a DermSecure™ roll-out with its Spanish distribution partner as well as plans for the US, Mexico, and the Netherlands. MedX’s DermSecure™ has been built to the leading data repository standards to allow for integration with
Aug 23, 2018 08:30 am ET
MedX Health Corp. Announces Second Quarter 2018 Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three and six months ended June 30, 2018, which are also available on SEDAR (www.sedar.com).
Aug 09, 2018 10:53 am ET
MedX Health Corp. Announces Dermatologist Dr. Trevor Champagne, from Toronto’s Women's College Hospital, has Joined Medical Advisory Board
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Trevor Champagne, Clinician in Quality and Innovation at Toronto’s Women's College Hospital, has joined its Medical Advisory Board. He is a board certified dermatologist in Canada and the US.
May 29, 2018 06:30 pm ET
MedX Health Corp. Announces First Quarter 2018 Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three months ended March 31, 2018, which are also available on SEDAR (www.sedar.com).
May 23, 2018 08:00 am ET
Dr. Daniel Siegel, Professor of Dermatology and former President of the American Academy of Dermatology joins MedX’s Medical Advisory Board
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that Dr. Daniel Siegel, Clinical Professor of Dermatology at SUNY Downstate in Brooklyn, New York, and a former President of the American Academy of Dermatology has joined its Medical Advisory Board.
May 14, 2018 08:35 am ET
MedX Health Corp.’s SIAscopy Technology Being Introduced to the Spanish Market
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced that it has shipped an initial order in excess of $120,000 of its SIAscopy technology to Spain through its marketing partnership with OncoTech LLC.
Apr 30, 2018 07:40 pm ET
MedX Health Corp. Announces 2017 Year End Results and Granting of Share Options
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the year ended December 31, 2017, which are also available on SEDAR (www.sedar.com).
Apr 04, 2018 08:00 am ET
MedX Health Corp. Adds Experienced Medical Device Professional, Scott Spearn, as President, to Build Sales and Expand Sales Channels
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Scott Spearn, an experienced medical device executive, joined the MedX team as President. Mr. Spearn has successfully built sales and distribution channels for medical devices across Canada, the United States and Latin America. His focus will be on developing and expanding MedX’s North American and international sales. Mr. Spearn will report to Robert von der Porten, CEO.
Mar 07, 2018 07:53 pm ET
MedX Health Corp. Announces Investor Relations Agreement
MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX). The Company announces that it has received notice from the TSX-V accepting an Investor Relations Agreement entered into with Mi3 Communications Financières Inc. (the “Consultant”) with an effective date of December 1, 2017. Under the terms of the Agreement, the Consultant will carry out activities to develop the Eastern Canada shareholder base of the Company, and the Company will pay to the Consultant a monthly consideration of $5,000, together with any pre-approved expenses, for a
Feb 28, 2018 08:00 am ET
MedX Health Corp. Announces Regulatory Clearance for its SIAscopy Medical Devices in New Zealand
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today it has received regulatory clearance from the New Zealand Medicines and Medical Devices safety authority (Medsafe WAND) to sell its SIAscope medical device in New Zealand.
Feb 13, 2018 04:40 pm ET
MedX Receives Corporate Citizenship Award from the Melanoma Network of Canada
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that it received a Corporate Citizenship Award from the Melanoma Network of Canada (“MNC”) for MedX’s work in raising melanoma awareness.
Jan 30, 2018 10:01 am ET
MedX Health Corp. Announces SIAscopy Order Exceeding $100,000 for Spain
MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce that it received an initial order in excess of $100,000 for its pain-free, non-invasive skin assessment SIAscopy technology for use in Spain through its marketing partnership with OncoTech LLC. In May 2017, MedX announced that OncoTech, a US-based company which has built strong business relationships in Spain, Mexico and Colombia, would help MedX establish and grow sales in these Latin countries.
Jan 24, 2018 09:43 am ET
MedX Health Corp. Announces Closing of Private Placement
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX):
Jan 08, 2018 04:05 pm ET
MedX Health Corp. Announces Proposed Private Placement
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that it intends to raise up to a further $1,500,000 from accredited investors, by issuance of up to 12,500,000 Units, at $0.12 per Unit. Upon closing, this proposed placement will complete the amount of the financing originally announced in March, 2017, at which time the proposed placement was being offered on a brokered basis. The current portion of the proposed financing is being offered by the Company on a non-brokered basis but is otherwise on the same terms as the placements
Dec 18, 2017 06:29 pm ET
MedX Health Corp. Announces Closing of Private Placement
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX). The Company announces that, effective December 15, 2017, it closed a non-brokered private placement. On Closing of the placement, the Company raised gross proceeds of $725,679 to its treasury by issuance of 6,047,329 Units, comprising 6,047,329 common shares (“Share(s)”) and 6,047,329 share purchase warrants (“Warrants”) at $0.12 per Unit. Each Warrant entitles the holder to purchase one additional Share during the period expiring December 15, 2020, at $0.20 per share. At Closing, a total
Nov 29, 2017 06:00 pm ET
MedX Health Corp. Announces Revenue Growth in its Third Quarter 2017 Results
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three and nine months ended September 30, 2017, which are also available on SEDAR (www.sedar.com).
Nov 29, 2017 08:22 am ET
MedX Health Corp. Announces Launch of Skin Scanning Service in the Netherlands
MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce that its channel partner, Nationale Healthcheck (“NH”), has launched its skin assessment service using SIAscopy in the Netherlands.
Nov 13, 2017 08:43 am ET
MedX Health Corp. Announces the Addition of Two Renowned International Skin Cancer Specialists to its Medical Scientific Advisory Board
MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce that Dr. Per Hall and Dr. Joe Walls, internationally renowned for their research on skin cancers and published authors of peer-reviewed research papers, have joined its Medical Scientific Advisory Board.
Oct 30, 2017 11:50 am ET
MedX Health Corp. and Blanc Labs Complete Design of Cloud-Based Telemedicine Platform to Enable Global Deployment of MedX’s Scanning Devices across a Broad Network of Centers
MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce that it has completed the design phase of its telemedicine platform which will allow MedX’s scanning devices to be deployed in multiple points of service in North America and internationally. The scanned images will be sent securely to dermatologists for remote assessment, allowing for accelerated referral for patients to an in-person consultation with a dermatologist for the treatment of suspicious cases.
Oct 12, 2017 10:46 am ET
MedX Health and Calian’s Primacy Management Join Together to Provide On-the-Spot Suspicious Mole and Lesion Scans at the Melanoma Network of Canada’s “Strides for Melanoma Walk for Awareness” Fundrais
MedX Health Corp. (“MedX”) (TSX-V: MDX) notes that despite unusually sweltering heat in Toronto, hundreds of people participated in the Strides for Melanoma Walk for Awareness on Sunday, September 24 in Sunnybrook Park. The annual event, which included concurrent 5Km walks in cities across Canada, is a key fundraiser organized by the Melanoma Network of Canada (“MNC”), a national skin cancer patient advocacy and educational network.
Aug 23, 2017 10:15 pm ET
MedX Health Corp. Announces Continued Improved Revenues in its Second Quarter 2017 Results
MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) announced its results for the three and six months ended June 30, 2017, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $236,892 for the three months...
Jul 14, 2017 06:00 pm ET
MedX Health Corp. Announces Further Closing of Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESMedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX). The Company announced that, effective July 14, 2017, it closed the second and final tranche of a...
Jun 09, 2017 06:00 pm ET
MedX Health Corp. Extends the Closing Period of Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESMedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX), announces that it has obtained acceptance from the TSX-V for an extension of time for the closing...
May 25, 2017 09:00 am ET
MedX Health Corp. and Melanoma Network of Canada announce strategic partnership: Collaborating on occupational health and safety offering for corporate Canada and their employees
MedX Health Corp. ("MedX") (TSX VENTURE: MDX) is pleased to announce its ground-breaking partnership with the Melanoma Network of Canada ("MNC"). The MNC is a national organization that provides melanoma awareness and prevention information to the...
May 24, 2017 08:04 am ET
MedX Health Corp. announces Joint Venture Marketing Partnership with OncoTech LLC
MedX Health Corp. ("MedX") (TSX VENTURE: MDX) is pleased to announce that it has partnered with OncoTech LLC ("OncoTech"), a US-based company, to develop the market for MedX's SIAscopy products in Mexico, Colombia and Spain, as well as selected...
May 23, 2017 01:29 pm ET
MedX Health Corp. Announces Improved Revenues in First Quarter 2017 Results
MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) announced its results for the three months ended March 31, 2017, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $239,810 for the three months ended...
May 09, 2017 09:08 pm ET
MedX Health Corp. Extends the Closing Period of Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESMedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) announces that it has obtained acceptance from the TSX-V for an extension of time for the closing...
May 03, 2017 10:23 am ET
MedX Health Corp. announces that Dr. Paul Cohen, renowned board certified dermatologist, joins MedX Medical/Scientific Advisory Board
MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) is pleased to announce that it has appointed Dr. Paul Cohen, a board certified dermatologist and Fellow of the Royal College of Physicians and Surgeons of Canada, to its...
May 01, 2017 10:16 pm ET
MedX Health Corp. announces 2016 Year End Results
MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) announced its results for the year ended December 31, 2016, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $817,055 for the year ended December 31,...
Apr 26, 2017 08:22 am ET
MedX Health Corp. signs a Memorandum of Understanding with MP Medic -- expected to help alleviate long dermatologist wait times in Quebec and expand MedX's reach in Canada
MedX Health Corp. ("MedX") (TSX VENTURE: MDX) is pleased to announce that it has entered into a Memorandum of Understanding with MP Médic, an aesthetic medicine firm located in Quebec, to deploy MedX's SIAscopy skin imaging technology throughout the...
Apr 25, 2017 05:50 pm ET
MedX Health Corp. Announces Closing of Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESMedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX). The Company announces that, effective April 21, 2017, it closed the first tranche of a brokered...
Apr 20, 2017 02:53 pm ET
MedX Health Corp. announces the introduction of its SIAscopy skin imaging devices with a chain of Netherlands based health clinics
MedX Health Corp. ("MedX") (TSX VENTURE: MDX) is pleased to announce that it has entered into an agreement with Health Consultant BV ("HCBV"), a Netherlands based company, to deploy MedX's SIAscopy skin imaging technology in health and wellness...
Mar 09, 2017 04:30 pm ET
MedX Health Corp. Announces Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESMedX Health Corp. ("MedX") (TSX VENTURE: MDX) is pleased to announce that it has entered into an engagement letter dated March 8, 2017, with Wildlaw Capital...
Feb 15, 2017 08:23 am ET
MedX Health Corp. announces that Dr. Dennis Reich, medical technology devices and software solutions innovator, joins Advisory Board
MedX Health Corp. ("MedX") (TSX VENTURE: MDX) is pleased to announce that it has appointed Dr. Dennis Reich to its Medical/Scientific Advisory Board. Dr. Reich is a successful entrepreneur and medical technology advisor as well as a practicing...
Jan 20, 2017 03:40 pm ET
MedX Health Corp. Announces Amendments to $500,000 Term Loan
MedX Health Corp. ("MedX") (TSX VENTURE: MDX) announced that it has agreed with a lender to amend the terms of an original $500,000 Term Loan. Under the New Terms, the Lender has the right to convert the Principal of the Loan, in whole or part, at...
Dec 21, 2016 02:12 pm ET
MedX Health Corp. appoints Scott Naughton, experienced C-level executive in dermatological and plastic surgery markets as Managing Director, US operations
MedX Health Corp. ("MedX") (TSX VENTURE: MDX) announced today that it has appointed Scott Naughton, Managing Director, US operations. Mr. Naughton has participated in the Senior Management of several US-based medical device and medical service...
Nov 28, 2016 04:50 pm ET
MedX Health Corp. Announces Third Quarter 2016 Financial Results and Issuance of Shares
MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) announced its results for the three and nine months ended September 30, 2016, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $317,420 for the three...
Oct 19, 2016 08:43 am ET
MedX Health hires Deborah Thompson, veteran communications and media relations expert, to help raise profile, grow business in Canada and globally
Rob von der Porten, President and CEO of MedX Health Corp. ("MedX") (TSX VENTURE: MDX), a medical device company, today announced that Ms. Deborah Thompson, a veteran media and investor relations professional from Bay Street, has been retained to...
Sep 15, 2016 05:12 pm ET
MedX Health Corp. Announces Closing of Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESMedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX). The Company announces it has closed a final tranche of a previously announced non-brokered...
Sep 02, 2016 06:10 pm ET
MedX Health Corp. Announces Third Closing of Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESMedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX). The Company announces it has closed a third tranche of a previously announced non-brokered...
Aug 26, 2016 09:16 am ET
MedX Health Corp. Announces Second Quarter 2016 Financial Results, Amendment to Stock Option Plan, and Option Grants
MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) announced its results for the three and six month ended June 30, 2016, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $209,496 for the three months...
Aug 16, 2016 08:16 pm ET
MedX Health Corp. Continuing to Receive Subscriptions for Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESMedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX). The Company announces it is extending the completion of a third tranche of a previously announced...
Aug 02, 2016 08:26 pm ET
MedX Health Corp. Announces Second Closing of Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESMedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX). The Company announces it has closed a second tranche of a previously announced non-brokered...
Jul 13, 2016 10:02 pm ET
MedX Health Corp. Continuing to Receive Subscriptions for Second Tranche of Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESMedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX). The Company announces it is extending the completion of a second tranche of a previously...
Jun 06, 2016 07:30 pm ET
MedX Health Corp. Announces Closing of Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESMedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) announces it has closed a tranche of a previously announced non-brokered private placement. The...
Jun 03, 2016 07:26 am ET
MedX Health Corp. Announces Ontario Launch With Lovell Pharmacies and the Ontario Telemedicine Network (OTN)
MedX Health Corp. ("MedX") (TSX VENTURE: MDX) announced today that it has reached an agreement with Lovell Drugs ("Lovell") and the Ontario Telemedicine Network ("OTN") to introduce in-pharmacy scanning of moles and lesions at a Lovell Drugs...
May 30, 2016 07:45 pm ET
MedX Health Corp. Announces First Quarter 2016 Financial Results and Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) announced its results for the three months ended March 31, 2016, which are also available...
Apr 29, 2016 06:17 pm ET
MedX Health Corp. Announces a 34% Revenue Increase in Its 2015 Year End Financial Results
MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) announced its results for the year ended December 31, 2015, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $1,171,421 for the year ended December 31,...
Mar 31, 2016 08:21 am ET
MedX Health Corp. Increases International Footprint -- Major Milestone in Turkey
MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX), a leading medical device company, MedX Health Corp. announced today that it has received Ministry of Health official registration in Turkey, allowing MedX to sell its SIAscopy based...
Feb 24, 2016 08:27 am ET
MedX Health Corp. Expands Capability in Europe
MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX), a leading medical device company, is expanding its growth capacity with the addition of Daniel Kaute as Managing Director, Europe. Daniel holds a PhD in materials engineering and has...